XBiotech begins development of an antibody therapy for MRSA
Product comes out of True Human antibody discovery programme for identifying and cloning pharmacologically relevant antibodies from human donors
XBiotech, a biopharmaceutical firm based on Austin, Texas, US, has completed discovery and has begun pre-clinical development of a new variant of its True Human antibody therapy for methicillin resistant staphylococcus aureus (MRSA).
XBiotech’s leading product candidate inhibits chronic (sterile) inflammation – a condition involved in the progression of many serious and common diseases. The company has several clinical trial programmes under development in several areas of medicine, including dermatology, oncology, diabetes, cachexia and cardiovascular disease.
The company believes the therapy could be a breakthrough in the management of drug resistant staphylococcus infections.
The MRSA antibody came out of XBiotech's True Human antibody discovery programme for identifying and cloning pharmacologically relevant antibodies from human donors. The company expects the product candidate to enter human clinical trials next year.
XBiotech's CEO John Simard said: 'To date, XBiotech has made significant strides on the discovery and development of anti-inflammatory antibodies.
'We are now truly excited about the possibility of revolutionising the management of infectious disease through the use of shared natural immunity with True Human therapeutic antibodies. Needless to say, we are eager to see this important therapy in the clinic.'